Bohai New Enzyme
Bohai New Enzyme is a special enzyme research and development manufacturer
About Bohai New Enzyme
Hzymes.com is a biotechnology startup that specializes in the production and sale of various types of enzymes and diagnostic reagent kits. The company operates in the biotechnology and healthcare markets, serving a wide range of clients, including research institutions, hospitals, and other healthcare providers.
The company's product portfolio includes Proteinase K in various forms (dry powder, solution, solid, diluted), virus DNA/RNA extraction kits, high-density lipoprotein cholesterol (HDL-C) test kits, and various other diagnostic reagent kits. These products are used in various medical and research applications, such as genetic testing, disease diagnosis, and biomedical research.
Hzymes.com operates on a business-to-business (B2B) model, selling its products directly to institutions and businesses in the healthcare and biotechnology sectors. The company generates revenue through the sale of its products. The prices of the products are not listed on the website and potential customers are asked to contact customer service for pricing information, suggesting a customized pricing strategy based on the specific needs and requirements of each client.
The company also appears to be actively involved in industry events and forums, as evidenced by the various invitations to medical equipment exhibitions and peptide and nucleic acid drug innovation forums listed on the website. This suggests that the company is committed to staying at the forefront of industry developments and maintaining strong relationships with its clients and partners.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Nov 2021 | $110M | $440M | Guoke Jiahe (Beijing) Investment Management · GF Qianhe | — |
| SERIES AOther financing | Jul 2018 | — | — | Sunz Fund | — |
Growth signals
Latest recorded traffic for Bohai New Enzyme is 2.1K monthly website visits, up 118.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Bohai New Enzyme in the Huangpu ecosystem
The Bohai New Enzyme office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- SFSunz Fund
Series B and later2 investors entered at this stage
- GMGuoke Jiahe (Beijing) Investment Management
GF Qianhe
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bohai New Enzyme on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bohai New Enzyme’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










